Recombinant batroxobin (Wansheng Biotech/Wanxing Biotech/Tenry Pharmaceutical)

重组巴曲酶（万盛生物/万兴生物/腾瑞制药）

Report date: 2026/04/23 16:25:07

Base Information

Drug NameRecombinant batroxobin (Wansheng Biotech/Wanxing Biotech/Tenry Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionFibrinogen inhibitors
TargetsFibrinogen
Therapy Area/IndicationsHemorrhageHemorrhagic Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Wanxing Biological Pharmaceutical Co LtdShanghai Tenry Pharmaceutical Co LtdShanghai Wansheng Biological Technology Development Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Wanxing Biological Pharmaceutical Co Ltd
Inactive CompaniesShanghai Tenry Pharmaceutical Co Ltd
Active IndicationsHemorrhage
Inactive IndicationsHemorrhagic Disorders

Other Information

ATC CodeN/A
Related LinksN/A